USPatentGranted
B2

Treatment of macrophage mediated disease

Granted 15 Dec 2009 · 10 office actions

Assignee: Purdue University

Law firm: Law firm · Log in to unlock

Attorney: Attorney · Log in to unlock

Inventors: Philip S. Low, Mary Jo Turk · Examiner: Michail A Belyavskyi · AU 1644 · TC 1600

Life of the patent

21 dated events
⤢ drag to zoom20022004200620082010201220142016201820202022ProsecutionTerm & fees
ProsecutionTerm & feeshover for detail · click to open

Abstract

The invention relates to a method of treating or monitoring/diagnosing a disease state mediated by activated macrophages. The method comprises the step of administering to a patient suffering from a macrophage mediated disease state an effective amount of a composition comprising a conjugate or complex of the general formula A b -X where the group A b comprises a ligand capable of binding to activated macrophages, and when the conjugate is being used for treatment of the disease state, the group X comprises an immunogen, a cytotoxin, or a compound capable of altering macrophage function, and when the conjugate is being used for monitoring/diagnosing the disease state, X comprises an imaging agent. The method is useful for treating a patient suffering from a disease selected from the group consisting of rheumatoid arthritis, ulcerative colitis, Crohn\'s disease, inflammation, infections, osteomyelitis, atherosclerosis, organ transplant rejection, pulmonary fibrosis, sarcoidosis, and systemic sclerosis.

Claims

17 · 2 independent · depth 3
1234567891011121314151617
17 granted claims

Classifications

6 codes
IPC · International Patent Classification
Section A — Human necessities
  • A61K39/00
  • A61K39/38
  • A61K39/385
USPC · US Patent Classification
424/184.1424/193.1424/185.1

Claim changes

Soon
Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom200220032004200520062007200820092010USPTOApplicantRestriction requirementNon-final rejectionFinal rejectionAdvisory actionRequest for continued examinationResponse after non-finalNotice of appeal filedRequest for continued examinationNotice of allowance
USPTOApplicanthover for detail · click to open
Pendency
7.6 y
2,784 days filing → grant
Office actions
5
after a restriction
Responses
5
2 RCE
Interviews
1
examiner interview summaries
Examiner
Michail A Belyavskyi
art unit 1644 · TC 1600
Citations: 72 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Log in to unlock

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Log in to unlock

Priority chain

2 priority documents
Priority
2 May 2001
earliest claimed
›Priority documents — 2
TypeDocumentDate
provisionalUS 60288208 002 May 2001
related publicationUS 20020192157 A119 Dec 2002

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Log in to unlock

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.

Log in to unlock